A retrospective analysis of six departed regulators has revealed an observational association with highly compensated private-sector executive roles, but experts warn against jumping to conclusions based on a sample size of six.
A qualitative analysis of six former Food and Drug Administration officials has revealed a strong observational association between departing the federal regulatory agency and immediately accepting a highly compensated executive position at a major pharmaceutical manufacturer. However, the subjects involved have urged industry observers to interpret the findings with extreme caution, noting that a sample size of six is far too small to establish definitive causality.
Published this week as an anecdotal case series in STAT, the accounts track the career trajectories of a small cohort of regulators who left government service over the past twelve months. While initial data points indicate a 100 percent transition rate into private-sector lobbying firms and board seats at Pfizer, Merck, and Eli Lilly, researchers stress that these outcomes have not yet been evaluated in a randomized, double-blind setting.
While the temporal proximity of these resignations and the subjects' subsequent appointments as senior vice presidents at Novartis is certainly an interesting data point, we must remember that correlation does not imply a causal link to the signing bonuses.
The former officials pointed to numerous confounding variables that could explain the phenomenon, including an organically occurring desire to optimize shareholder value and a spontaneous, late-onset passion for corporate synergy. Furthermore, independent experts warn that the preliminary findings rely heavily on self-reported narratives, which are inherently subject to recall bias, unmeasured variables, and stringent non-disclosure agreements.
Until a more robust, multi-center longitudinal study can be conducted to track the officials' stock options over a five-to-ten-year period, health policy analysts recommend treating the sudden alignment between federal regulatory approvals and immediate pharmaceutical employment as a promising but unverified hypothesis.